The Fumarprotocetraric Acid Inhibits Tau Covalently, Avoiding Cytotoxicity of Aggregates in Cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Fumarprotocetraric Acid Inhibits Tau Covalently, Avoiding Cytotoxicity of Aggregates in Cells
Authors
Keywords
-
Journal
MOLECULES
Volume 26, Issue 12, Pages 3760
Publisher
MDPI AG
Online
2021-06-21
DOI
10.3390/molecules26123760
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity
- (2021) Luciana Medina et al. Frontiers in Aging Neuroscience
- Targeting tau: Clinical trials and novel therapeutic approaches
- (2020) Lawren VandeVrede et al. NEUROSCIENCE LETTERS
- Anthraquinone Derivative Reduces Tau Oligomer Progression by Inhibiting Cysteine-Cysteine Interaction
- (2019) Carlos Areche et al. ChemistryOpen
- 2018 Alzheimer's disease facts and figures
- (2018) Alzheimers & Dementia
- Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
- (2018) Fuyuki Kametani et al. Frontiers in Neuroscience
- Fulvic Acid Inhibits Aggregation and Promotes Disassembly of Tau Fibrils Associated with Alzheimer's Disease
- (2018) Alberto Cornejo et al. JOURNAL OF ALZHEIMERS DISEASE
- Interaction of Cinnamaldehyde and Epicatechin with Tau: Implications of Beneficial Effects in Modulating Alzheimer's Disease Pathogenesis
- (2018) Roshni C. George et al. JOURNAL OF ALZHEIMERS DISEASE
- Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial
- (2016) Serge Gauthier et al. LANCET
- Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
- (2015) Roberto Bomprezzi Therapeutic Advances in Neurological Disorders
- Resonance Raman Spectroscopic Measurements Delineate the Structural Changes that Occur during Tau Fibril Formation
- (2014) Gayathri Ramachandran et al. BIOCHEMISTRY
- Tau-aggregation inhibitor therapy for Alzheimer's disease
- (2013) Claude M. Wischik et al. BIOCHEMICAL PHARMACOLOGY
- Dimethyl Fumarate for Treatment of Multiple Sclerosis: Mechanism of Action, Effectiveness, and Side Effects
- (2013) Ralf A. Linker et al. Current Neurology and Neuroscience Reports
- Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology
- (2013) Katja Hochgräfe et al. FEBS Journal
- Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation
- (2013) Alex Crowe et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tau pathology and neurodegeneration
- (2013) Maria Grazia Spillantini et al. LANCET NEUROLOGY
- Tau-targeted treatment strategies in Alzheimer's disease
- (2011) Jürgen Götz et al. BRITISH JOURNAL OF PHARMACOLOGY
- Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
- (2008) C.-X. Gong et al. CURRENT MEDICINAL CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started